StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Tukysa (tucatinib by Quarter

Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Tukysa (tucatinib: $96M in Q2 2026, down 10.3% from a year earlier.

Latest, Q2 2026
96
Period ended Jun 28, 2026
Change on a year earlier
-10.3%
107 in Q2 2025
History
11 quarters
Since Q4 2023
Sources
7
Documents cited below

Where the Q2 2026 figure comes from

“|| Tukysa | 138 | 132 | 5% | 4% | 96 | 107 | (11%) | 42 | 24 | 73% | 67%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — U.S. revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 202696-10.3%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202695+14.5%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202584-20.8%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202579-18.6%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025107+10.3%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 202583-6.7%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024106+488.9%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 202497–Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 202497–Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 202489–Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 202318–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗

Breakdown

What makes up tukysa (tucatinib

Cite this data

StockData. (2026). Pfizer Tukysa (tucatinib ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/tukysa-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.